India's only domestically developed COVID-19 vaccine, Covaxin, has been found to be 78% effective in a second analysis of clinical trials done around the country, its makers said here on Wednesday.
“I am very pleased to state that Covaxin ... has shown the efficacy of 78% in the second interim analysis,” said Balram Bhargava, the chief of the state-run Indian Council of Medical Research that has created the vaccine with Bharat Biotech.
The first analysis released in March had shown an efficacy rate of 81%.
- DigitALL: Innovation And technology For Gender Equality
- Mar 08, 2023
- India Says It Will Protect Its Interests As Chinese Boat Heads To Sri Lanka
- Jul 30, 2022
- Omicron Poses 'Very High' Global Risk, World Must Prepare: WHO
- Nov 29, 2021
- Resumption Of India's COVAX Vaccine Supply Delayed By Nepal
- Nov 24, 2021
- US Shipping 1.5 Million J&J Vaccines To Nepal
- Jul 10, 2021
